VBL Therapeutics Opens New Gene Therapy Manufacturing Plant

VBL Therapeutics (NASDAQ:VBLT) announced the opening of its new gene therapy manufacturing plant in Modiin, Israel.
As quoted in the press release:

This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec (VB-111), if approved.

The Modiin facility is the first commercial-scale gene therapy manufacturing facility in Israel and currently one of the largest gene-therapy designated ones in the world (20,000 sq. ft.). It is capable of manufacturing in large-scale capacity of 1,000 liters and is scalable to 2,000 liters.
“Having a manufacturing facility in place is an important step as we make preparations for potential regulatory approval and commercialization of VB-111,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.

Click here to read the full press release.

Source: globenewswire.com